Ian Brokaw, DPT | |
65 Albany Tpke, Canton, CT 06019-2507 | |
(860) 693-6226 | |
(860) 693-8002 |
Full Name | Ian Brokaw |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 65 Albany Tpke, Canton, Connecticut |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356838262 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2081S0010X | Physical Medicine & Rehabilitation - Sports Medicine | 10642 (Connecticut) | Secondary |
208100000X | Physical Medicine & Rehabilitation | 10642 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ian Brokaw, DPT Po Box 466, Canton, CT 06019-0466 Ph: (860) 693-6226 | Ian Brokaw, DPT 65 Albany Tpke, Canton, CT 06019-2507 Ph: (860) 693-6226 |
News Archive
PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, today announced the launch of its AxION™ Mass Spectrometry platform at the American Society for Mass Spectrometry (ASMS) Conference, June 5-9, in Denver, Colorado.
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the "Units"), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.
GlaxoSmithKline has announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510 million (euro 340 million). The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.
Today is World Sleep Day, an annual global event that aims to improve sleep health worldwide. World Sleep Day is organized by the World Association of Sleep Medicine (WASM) to spread awareness of important sleep-related issues and the burden insomnia places on society through a series of special events. This year it is focussing on sleep loss resulting from the need to urinate during the night.
Bristol-Myers Squibb Company and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.
› Verified 1 days ago
Alysha Seickel, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 191 Albany Tpke Ste 104, Canton, CT 06019 Phone: 203-788-0009 |